AbbVie (ABBV) News
NYSE: ABBVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
276.47+4.05 (+1.49%)
At close: Oct 9, 4:01 PM ET · Delayed 15 min
ABBV news summary
We found 44 recent headlines mentioning AbbVie (ABBV): 28 in the past week and 38 in the past 30 days, most often from Nasdaq, Seeking Alpha, Investor's Business Daily. For price context, ABBV is up 1.49% at $276.47. The most recent story, "Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest AbbVie headlines
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) - This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.NasdaqABBV, ALVO, ARGX, BBIO
- TDVG, CB, BAC, ABBV: Large Outflows Detected at ETFLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the T. Rowe Price Dividend Growth ETF (Symbol: TDVG) where we have…NasdaqTDVG, CB, BAC, ABBV
- A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That HappensKey PointsAbbVie has a diversified portfolio of drugs and a deep pipeline that could help it overcome patent cliffs.NasdaqABBV, AMGN
- Cancer Stocks to Consider as Oncology Innovation AcceleratesOncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.NasdaqABT, PFE, MMSI, AZN
- Dividend Roundup: Starbucks, Pfizer, Micron, AbbVie, and moreSeeking AlphaPFE, ABBV, SBUX
- AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in CancerABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.NasdaqABBV, BMY, CRSP, ACTU
- Biotech Stocks At 52-Week Highs - ABBV On FDA Designations, HSTM, OGN(RTTNews) - The following biotech stocks reached a 52-week high on October 6, 2026, driven by catalysts such as achieving new regulatory milestones.NasdaqABBV, HSTM, OGN, BRK.A
- AbbVie options flow shows 4:1 call-to-put ratio as stock risesInvesting.com
- 5 Stocks to Buy That Have Raised Their Dividends Every Year Since 2000Key PointsDividend yield is great, but if you want to build long-term wealth, it's more important to prioritize dividend growth.NasdaqCAT, IBM, KO, XOM
- Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.NasdaqIRWD, AZN, ABBV
- AbbVie's Temab-A Earns FDA Breakthrough Therapy Designations In CRC, NSCLC;Stock Up(RTTNews) - AbbVie (ABBV), a biopharmaceutical company, announced that the U.S. FDA has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal…Nasdaq
- AbbVie's Telisotuzumab Adizutecan Secures Dual FDA Breakthrough Therapy Designations(RTTNews) - Wednesday, AbbVie Inc. (ABBV) announced that the U.S. Food and Drug Administration has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan or Temab-A in colorectal…Nasdaq
- Stock Market Today: Dow Cuts Sharp Losses As Some Techs Rally; AbbVie Breaks Out (Live Coverage)The Dow Jones index drops 500 points Wednesday as Treasury yields jump. The Fed minutes are due later in the day. The post Stock Market Today: Dow Cuts Sharp Losses As Some Techs Rally; AbbVie Breaks…Investor's Business Daily
- 3 of the Best Growth Stocks to Buy in October 2026Key PointsThe stocks listed here are trading at modest earnings multiples.NasdaqAMZN, ABBV, NFLX
- HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.Key PointsOne analyst sees expanded uses for Rinvoq and Skyrizi propelling AbbVie stock to as much as $315 per share.NasdaqABBV, HSBC
- AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCLABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.NasdaqABBV, GMAB, PFE, FRO
- Should You Buy AbbVie Stock Before Oct. 30?Key PointsAbbVie has generated solid double-digit growth in its most recent quarters.Nasdaq
- Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after…Nasdaq
- AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS & Cuts Progression Risk In Lymphoma(RTTNews) - AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large…NasdaqABBV, GMAB
- AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS In DLBCL(RTTNews) - AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large…NasdaqABBV, GMAB
- AbbVie flags $216M IPR&D and milestones expense for Q3Seeking Alpha
- AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer ContenderThe addition of Genmab's Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening. Genmab stock rocketed. The post AbbVie Partner Flies Sky-High On News For Its…Investor's Business DailyNWS, ABBV
- Why AbbVie (ABBV) Outpaced the Stock Market TodayAbbVie (ABBV) closed at $265.85 in the latest trading session, marking a +1.15% move from the prior day.Nasdaq
- Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in OctoberKey PointsAbbVie is a Dividend King with plenty of irons in the fire.NasdaqABBV, MDT, MMED
- FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line SettingLLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.NasdaqLLY, AZN, JNJ, ABBV
- AbbVie Joins Federal 340B Rebate Pilot Program Ahead Of 2027 Launch(RTTNews) - AbbVie (ABBV) on October 2, Friday announced that it has been approved to participate in the federal 340B Rebate Model Pilot Program, a government initiative aimed at improving pricing…Nasdaq
- AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilotSeeking AlphaAMGN, ABBV, PFE
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury NoteThe 10-year Treasury note yielded around 5.3% in late September. One month before, it was around 4.78%, and it's up by more than a full percentage point from where it was one year ago. To put that…NasdaqPFE, LLY, ABBV, MRK
- How to Create a Million-Dollar Stock PortfolioSuccessful stock investors have one thing in common: the power of compounding.NasdaqWFC, ABT, ABBV
- 3 of the Best ETFs to Buy and Hold if a Recession Is ComingKey PointsVHT is a diversified play on the non-cyclical healthcare sector.NasdaqMRK, MSFT, GOOGL, AAPL
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) - The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic…NasdaqABBV, AZN, CBLL, CDXS
- J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to WatchJNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.NasdaqJNJ, AZN, AMGN, ABBV
- Notable ETF Inflow Detected - XLV, ABBV, TMO, GILDLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where…NasdaqXLV, ABBV, TMO, GILD
- ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.NasdaqABBV, JNJ, MRK, LLY
- Top Research Reports for Alphabet, Mastercard & AbbVieAlphabet's AI-led cycle is strengthening Search, Cloud and subscriptions, while rising investment and regulatory risks create uncertainty around returns.NasdaqMA, ABBV, GOOGL, PPIH
- AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell'Seeking Alpha
- 2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVieSeeking AlphaJNJ, ABBV
- AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaABBV, MS
- AbbVie Inc. (ABBV) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha
- AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)Seeking Alpha
- AbbVie Still Has Room To RunSeeking Alpha
- Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.NasdaqIART, BDX, ABBV
- AbbVie: Strong Q2 And New Catalysts Keep Me BullishSeeking Alpha
- AbbVie Inc. (ABBV) Q2 2026 Earnings Call TranscriptSeeking Alpha